Taken together, high expression of FcγRIIb on TAMs and DCs may serve as a potential oncogenic driver through regulating the multiple immune-associated signaling pathways in recurrent GBM, indicating a promising therapeutic strategy of targeting FcγRIIb and the possibility of providing more treatment options to patients with recurrent GBM. This evidence concerns the gene FCGR2B and glioblastoma.